Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Open chromatin profiling as a novel strategy for identifying cancer cell of origin.

Literature DB >> 28090579

Open chromatin profiling as a novel strategy for identifying cancer cell of origin.

Abstract

Tumor cell of origin is an important prognostic measure but is challenging to assess. We recently demonstrated in acute myeloid leukemia (AML) that the chromatin landscape serves as a biomarker of transformed cell of origin. Thus, open chromatin loci offer important prognostic information as well as targets for development of novel therapies in cancer treatment.

Entities: Disease

Keywords: Acute myeloid leukemia; biomarker; chromatin; progenitor cell; stem cell

Year: 2016 PMID： 28090579 PMCID： PMC5160412 DOI： 10.1080/23723556.2016.1236770

Source DB: PubMed Journal: Mol Cell Oncol ISSN： 2372-3556

Keyword Cloud
References

7 in total

1. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Authors: A V Krivtsov; M E Figueroa; A U Sinha; M C Stubbs; Z Feng; P J M Valk; R Delwel; K Döhner; L Bullinger; A L Kung; A M Melnick; S A Armstrong
Journal: Leukemia Date: 2012-12-13 Impact factor: 11.528

Review 2. Cells of origin in cancer.

Authors: Jane E Visvader
Journal: Nature Date: 2011-01-20 Impact factor: 49.962

3. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.

Authors: Jason D Buenrostro; Paul G Giresi; Lisa C Zaba; Howard Y Chang; William J Greenleaf
Journal: Nat Methods Date: 2013-10-06 Impact factor: 28.547

Open chromatin profiling as a novel strategy for identifying cancer cell of origin.

1. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Review 2. Cells of origin in cancer.

3. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.

Review 4. Editing the epigenome: technologies for programmable transcription and epigenetic modulation.

5. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.

6. Leukaemia cell of origin identified by chromatin landscape of bulk tumour cells.

7. Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling.